A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.

N/A

Hebei Yanda Hospital

Beijing Tiantan Hospital

Lomustine
Procarbazine
Vincristine